{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=43",
    "query": {
      "condition": "Phase 2 Study",
      "page": 43
    },
    "page_size": 10
  },
  "pagination": {
    "page": 43,
    "page_size": 10,
    "total_count": 17257,
    "total_pages": 1726,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=44&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=42&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T21:34:31.043Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03423264",
      "title": "PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oropharyngeal Cancer",
        "HPV-Related Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Gabapentin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-01-22",
      "completion_date": "2022-11-08",
      "has_results": false,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-10-24T21:34:31.043Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03423264"
    },
    {
      "nct_id": "NCT00165230",
      "title": "Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Thalidomide",
          "type": "DRUG"
        },
        {
          "name": "Temodar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2002-05",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2009-04-28",
      "last_synced_at": "2026-10-24T21:34:31.043Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00165230"
    },
    {
      "nct_id": "NCT06680830",
      "title": "A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease",
        "Parkinson",
        "Idiopathic Parkinson Disease",
        "Early Parkinson Disease (Early PD)",
        "Parkinson Disease, Idiopathic"
      ],
      "interventions": [
        {
          "name": "NEU-411",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Neuron23 Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 150,
      "start_date": "2025-01-17",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-24T21:34:31.043Z",
      "location_count": 45,
      "location_summary": "Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06680830"
    },
    {
      "nct_id": "NCT00006471",
      "title": "Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Fenretinide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2000-09",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2018-11-01",
      "last_synced_at": "2026-10-24T21:34:31.043Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006471"
    },
    {
      "nct_id": "NCT00219609",
      "title": "Assessment Of Safety Of UK-390,957",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Ejaculation"
      ],
      "interventions": [
        {
          "name": "UK-390,957",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1058,
      "start_date": "2005-01",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2012-11-07",
      "last_synced_at": "2026-10-24T21:34:31.043Z",
      "location_count": 46,
      "location_summary": "Tucson, Arizona • Anaheim, California • Atherton, California + 43 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Atherton",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Laguna Woods",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00219609"
    },
    {
      "nct_id": "NCT00336700",
      "title": "A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Herbert J. Zeh, III MD, FACS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2006-06",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2016-09-19",
      "last_synced_at": "2026-10-24T21:34:31.043Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00336700"
    },
    {
      "nct_id": "NCT02978144",
      "title": "Lung Imaging of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "AxV-128/Tc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 34,
      "start_date": "2017-06-15",
      "completion_date": "2019-10-08",
      "has_results": true,
      "last_update_posted_date": "2025-10-09",
      "last_synced_at": "2026-10-24T21:34:31.043Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02978144"
    },
    {
      "nct_id": "NCT00773344",
      "title": "Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Tanespimycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2005-12",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2015-11-04",
      "last_synced_at": "2026-10-24T21:34:31.043Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • New York, New York",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00773344"
    },
    {
      "nct_id": "NCT02603809",
      "title": "Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Essential Hypertension"
      ],
      "interventions": [
        {
          "name": "Aprocitentan 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Aprocitentan 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Aprocitentan 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Aprocitentan 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Lisinopril 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idorsia Pharmaceuticals Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1659,
      "start_date": "2015-12-14",
      "completion_date": "2017-04-07",
      "has_results": true,
      "last_update_posted_date": "2022-11-23",
      "last_synced_at": "2026-10-24T21:34:31.043Z",
      "location_count": 74,
      "location_summary": "Fort Payne, Alabama • Chandler, Arizona • Peoria, Arizona + 62 more",
      "locations": [
        {
          "city": "Fort Payne",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02603809"
    },
    {
      "nct_id": "NCT02983799",
      "title": "Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity"
      ],
      "interventions": [
        {
          "name": "OLAPARIB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 272,
      "start_date": "2016-12-22",
      "completion_date": "2020-12-03",
      "has_results": true,
      "last_update_posted_date": "2022-04-13",
      "last_synced_at": "2026-10-24T21:34:31.043Z",
      "location_count": 35,
      "location_summary": "Anchorage, Alaska • La Jolla, California • Los Angeles, California + 29 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02983799"
    }
  ]
}